JP7492962B2 - 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療法 - Google Patents

置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療法 Download PDF

Info

Publication number
JP7492962B2
JP7492962B2 JP2021535546A JP2021535546A JP7492962B2 JP 7492962 B2 JP7492962 B2 JP 7492962B2 JP 2021535546 A JP2021535546 A JP 2021535546A JP 2021535546 A JP2021535546 A JP 2021535546A JP 7492962 B2 JP7492962 B2 JP 7492962B2
Authority
JP
Japan
Prior art keywords
phenyl
trifluoromethyl
oxo
cyano
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021535546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514347A (ja
JP2022514347A5 (https=
Inventor
アミランテ マッシモ
バフマンヤール ソゴール
ディー． コレア マシュー
グラント ヴァージニア
ハンセン ジョシュア
ジェイ． ホーン エヴァン
エス． ケルヒャー ティモシー
メイン クリストファー
エー． ナギー マーク
クリシュナ ナーラ ラマ
ナヤク スレンドラ
ノリス ステファン
パパ パトリック
プランテヴァン‐クレニツスキー ヴェロニク
ジェイ． サピエンザ ジョン
ダブリュー． ホワイトフィールド ブランドン
スー シュイチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2022514347A publication Critical patent/JP2022514347A/ja
Publication of JP2022514347A5 publication Critical patent/JP2022514347A5/ja
Application granted granted Critical
Publication of JP7492962B2 publication Critical patent/JP7492962B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021535546A 2018-12-19 2019-12-18 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療法 Active JP7492962B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862782281P 2018-12-19 2018-12-19
US62/782,281 2018-12-19
US201962879927P 2019-07-29 2019-07-29
US62/879,927 2019-07-29
PCT/US2019/067090 WO2020132016A1 (en) 2018-12-19 2019-12-18 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Publications (3)

Publication Number Publication Date
JP2022514347A JP2022514347A (ja) 2022-02-10
JP2022514347A5 JP2022514347A5 (https=) 2023-01-11
JP7492962B2 true JP7492962B2 (ja) 2024-05-30

Family

ID=71099150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535546A Active JP7492962B2 (ja) 2018-12-19 2019-12-18 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療法

Country Status (13)

Country Link
US (1) US11325889B2 (https=)
EP (1) EP3897635A4 (https=)
JP (1) JP7492962B2 (https=)
KR (1) KR102864064B1 (https=)
CN (1) CN113473987B (https=)
AU (1) AU2019404022A1 (https=)
BR (1) BR112021012186A2 (https=)
CA (1) CA3124101A1 (https=)
IL (1) IL284187A (https=)
MX (1) MX2021007475A (https=)
SG (1) SG11202106506WA (https=)
TW (1) TW202039434A (https=)
WO (1) WO2020132016A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024109765A (ja) * 2018-12-19 2024-08-14 セルジーン コーポレイション 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
EP4438603A4 (en) 2021-11-25 2025-06-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028226A1 (ja) 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha 新規イミダゾリジン誘導体およびその用途
JP2014510074A (ja) 2011-03-10 2014-04-24 スジョウ キンター ファーマシューティカルズ インコーポレイテッド アンドロゲン受容体アンタゴニストおよびその使用
JP2015526487A (ja) 2012-09-04 2015-09-10 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． イミダゾリン誘導体、その製造法、およびそれらの医薬への適用
US20180008587A1 (en) 2016-07-08 2018-01-11 Jaressen Pharmaceutica NV Thiohydantoin androgen receptor antagonists for the treatment of cancer
JP2018502925A (ja) 2015-01-20 2018-02-01 アルビナス インコーポレイテッド ターゲティングされたアンドロゲン受容体分解のための化合物および方法
US20180215731A1 (en) 2017-01-31 2018-08-02 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20180298021A1 (en) 2016-01-11 2018-10-18 Janssen Pharmaceutica Nv Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists
JP2022514344A (ja) 2018-12-19 2022-02-10 セルジーン コーポレイション 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302485A1 (de) * 1993-01-29 1994-08-04 Merck Patent Gmbh Piperazinderivate
FR2768728B1 (fr) 1997-09-19 1999-12-03 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
FR2768729A1 (fr) 1997-09-19 1999-03-26 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique et complexes catalytiques
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
RU2434851C1 (ru) 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
US20140112922A1 (en) 2011-03-28 2014-04-24 Cornell University Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
RU2683788C2 (ru) 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
RU2557235C1 (ru) 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
TWI739888B (zh) 2016-10-07 2021-09-21 美商陶氏農業科學公司 農藥組合物及方法
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
US10925868B2 (en) 2016-11-10 2021-02-23 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
WO2018098280A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
AU2017378943B2 (en) 2016-12-19 2020-06-18 Abbisko Therapeutics Co., Ltd. FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN109422725A (zh) 2017-09-04 2019-03-05 北京美倍他药物研究有限公司 前列腺癌治疗药物
ES2959954T3 (es) 2017-11-28 2024-02-29 Aarti Pharmalabs Ltd Proceso para la preparación de enzalutamida utilizando un nuevo intermedio
EP3720281A4 (en) 2017-12-05 2021-05-26 Dow Agrosciences LLC PESTICIDE COMPOSITIONS AND PROCEDURES
CN114835729B (zh) 2018-05-30 2024-05-31 江苏豪森药业集团有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN109651256A (zh) 2018-11-20 2019-04-19 上海健康医学院 一种式（viii）的恩杂鲁胺的制备方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028226A1 (ja) 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha 新規イミダゾリジン誘導体およびその用途
JP2014510074A (ja) 2011-03-10 2014-04-24 スジョウ キンター ファーマシューティカルズ インコーポレイテッド アンドロゲン受容体アンタゴニストおよびその使用
JP2015526487A (ja) 2012-09-04 2015-09-10 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． イミダゾリン誘導体、その製造法、およびそれらの医薬への適用
JP2018502925A (ja) 2015-01-20 2018-02-01 アルビナス インコーポレイテッド ターゲティングされたアンドロゲン受容体分解のための化合物および方法
US20180298021A1 (en) 2016-01-11 2018-10-18 Janssen Pharmaceutica Nv Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists
US20180008587A1 (en) 2016-07-08 2018-01-11 Jaressen Pharmaceutica NV Thiohydantoin androgen receptor antagonists for the treatment of cancer
US20180215731A1 (en) 2017-01-31 2018-08-02 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP2022514344A (ja) 2018-12-19 2022-02-10 セルジーン コーポレイション 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024109765A (ja) * 2018-12-19 2024-08-14 セルジーン コーポレイション 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法
JP7724911B2 (ja) 2018-12-19 2025-08-18 セルジーン コーポレイション 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法

Also Published As

Publication number Publication date
CA3124101A1 (en) 2020-06-25
TW202039434A (zh) 2020-11-01
EP3897635A4 (en) 2022-08-31
JP2022514347A (ja) 2022-02-10
AU2019404022A1 (en) 2021-07-08
US20200199074A1 (en) 2020-06-25
IL284187A (en) 2021-08-31
WO2020132016A1 (en) 2020-06-25
CN113473987B (zh) 2024-09-03
SG11202106506WA (en) 2021-07-29
US11325889B2 (en) 2022-05-10
KR102864064B1 (ko) 2025-09-24
CN113473987A (zh) 2021-10-01
KR20210118828A (ko) 2021-10-01
MX2021007475A (es) 2021-08-05
BR112021012186A2 (pt) 2021-08-31
EP3897635A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
JP7724911B2 (ja) 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法
JP7492962B2 (ja) 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療法
JP7781792B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP7781083B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526191A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526182A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526192A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
HK40061385A (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
HK40061385B (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240520

R150 Certificate of patent or registration of utility model

Ref document number: 7492962

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150